Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (1334)	1/27/1999 8:08:00 AM
From: Henry Niman	Respond to of 1722

On Jan 18 WSJ had a review on the Pharmaceutical Sector, emphasizing patent expirations in the next four years and a slowing growth rate. The report preceded the recent sector slide. The report indicated that advances in molecular biology will drive new products which will focus on genetically defined sub-populations, and those companies with a Hollywood type mentality of targeting blockbuster drugs will fail to keep up with companies targeting sub-populations. The article was followed by a similar review in the Financial Times on Jan 21. Both articles were similar because the stories were based on a Boston Consulting Group report on the Pharmaceutical Sector. Details of that report are now linked to the Biotech Boom section of biocognizance.com